- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Rubicon Research reported strong Q4 FY26 performance with revenue jumping 43.5% YoY to ₹5,139 crore. PAT more than doubled, growing 111.8% YoY to ₹768 crore. The company highlighted that ~98% of its revenue is USD denominated, with Q4 USD revenue reaching $56 million, a 35% increase YoY.
Key growth drivers include a focus on specialty and differentiated products, stable pricing, and a robust pipeline of 24 products under USFDA review. Rubicon has received 12 product approvals in FY26, with a strong 92% commercialization rate for approved products.
The company is strategically expanding its manufacturing capabilities, including qualifying the Pithampur site for USFDA inspections expected in Q1 CY27, which should boost gross margins. Rubicon also announced a dividend of 150% (₹1.50 per share). The management foresees continued strong revenue visibility in the coming quarters.